US Bancorp DE Has $15.57 Million Stock Holdings in The Clorox Company $CLX

Key Points

• US Bancorp DE has reduced its stake in The Clorox Company by 5.3%, owning approximately 0.11% of the company worth $15.57 million as of the latest SEC filing.
• Clorox reported earnings per share (EPS) of $2.87 for the last quarter, exceeding analyst expectations, along with a year-over-year revenue increase of 4.5%.
• The company announced a quarterly dividend of $1.24 per share, reflecting an annualized dividend yield of 4.1% and a payout ratio of 76.07%.

US Bancorp DE trimmed its stake in shares of The Clorox Company (NYSE:CLX - Free Report) by 5.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 129,673 shares of the company's stock after selling 7,258 shares during the quarter. US Bancorp DE owned approximately 0.11% of Clorox worth $15,570,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. American National Bank & Trust grew its holdings in Clorox by 69.5% during the 2nd quarter. American National Bank & Trust now owns 217 shares of the company's stock worth $26,000 after acquiring an additional 89 shares during the last quarter. Ransom Advisory Ltd bought a new stake in Clorox during the 1st quarter worth approximately $35,000. GW&K Investment Management LLC grew its holdings in Clorox by 239.1% during the 1st quarter. GW&K Investment Management LLC now owns 295 shares of the company's stock worth $43,000 after acquiring an additional 208 shares during the last quarter. Roble Belko & Company Inc grew its holdings in Clorox by 140.7% during the 1st quarter. Roble Belko & Company Inc now owns 361 shares of the company's stock worth $53,000 after acquiring an additional 211 shares during the last quarter. Finally, IMA Advisory Services Inc. bought a new stake in Clorox during the 1st quarter worth approximately $58,000. 78.53% of the stock is currently owned by institutional investors and hedge funds.

Clorox Stock Up 0.1%

Shares of NYSE CLX opened at $120.14 on Friday. The firm has a market cap of $14.63 billion, a PE ratio of 18.43, a P/E/G ratio of 0.98 and a beta of 0.52. The Clorox Company has a 12-month low of $116.53 and a 12-month high of $171.37. The company's fifty day simple moving average is $122.21 and its 200 day simple moving average is $128.69. The company has a quick ratio of 0.57, a current ratio of 0.84 and a debt-to-equity ratio of 5.15.

Clorox (NYSE:CLX - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.24 by $0.63. The business had revenue of $1.99 billion for the quarter, compared to analyst estimates of $1.94 billion. Clorox had a net margin of 11.40% and a return on equity of 377.86%. Clorox's revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.82 earnings per share. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. As a group, sell-side analysts forecast that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Clorox Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, November 6th. Investors of record on Wednesday, October 22nd will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Wednesday, October 22nd. This represents a $4.96 annualized dividend and a yield of 4.1%. Clorox's dividend payout ratio is currently 76.07%.

Insider Transactions at Clorox

In related news, COO Eric H. Reynolds sold 15,041 shares of the stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the transaction, the chief operating officer directly owned 54,221 shares of the company's stock, valued at $6,711,475.38. This represents a 21.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.57% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Barclays reduced their target price on shares of Clorox from $118.00 to $112.00 and set an "underweight" rating on the stock in a report on Tuesday, September 30th. Wells Fargo & Company reduced their target price on shares of Clorox from $130.00 to $125.00 and set an "equal weight" rating on the stock in a report on Thursday, September 25th. UBS Group reduced their target price on shares of Clorox from $134.00 to $128.00 and set a "neutral" rating on the stock in a report on Wednesday. JPMorgan Chase & Co. reduced their price objective on shares of Clorox from $135.00 to $127.00 and set a "neutral" rating on the stock in a research note on Friday. Finally, Bank of America reduced their price objective on shares of Clorox from $135.00 to $125.00 and set a "neutral" rating on the stock in a research note on Wednesday. One investment analyst has rated the stock with a Buy rating, eleven have assigned a Hold rating and three have given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Reduce" and a consensus target price of $131.92.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.